Rita Nanda, MD

Rita Nanda, MD, associate professor of medicine and director of the Breast Oncology Program at The University of Chicago, discusses the IMpassion130 trial in patients with metastatic triple-negative breast cancer (TNBC) who express PD-L1.

The IMpassion130 trial has been practice-changing for Nanda and many other providers, creating a new standard of care for women with metastatic TNBC whose cancer expresses the PD-L1 protein. Pembrolizumab is not yet approved in the neoadjuvant setting, but Nanda is hopeful it will come.

Videos

Rita Nanda, MD, discusses the IMpower130 trial in patients with metastatic triple-negative breast cancer who express PD-L1.

The IMpassion130 trial in Metastatic Triple-Negative Breast Cancer

Rita Nanda, MD, assistant professor of Medicine, assistant director, Breast Medical Oncology, discusses results from I-SPY 2, which explored pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer.&nbsp;

Results for Pembrolizumab Plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer

Most trials reported today are in metastatic TNBC, but areas that need more attention are HER2+ disease and hormone-refractory hormone-receptor positive breast cancer, said Nanda. Knowledge of the role of immune checkpoint inhibition within these subtypes of breast cancer is needed as well.

Nanda is also hoping combination therapy with immune checkpoint inhibitors, vaccines, and other therapies will help to improve the current response rates.

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the treatment of metastatic triple-negative breast cancer (TNBC).

Rita Nanda, MD | Authors

Articles

The IMpassion130 trial in Metastatic Triple-Negative Breast Cancer

Results for Pembrolizumab Plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer

Treatment of Metastatic Triple-Negative Breast Cancer